Coya Therapeutics (NASDAQ:COYA) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock.

COYA has been the subject of several other reports. Lake Street Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Wall Street Zen raised shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, January 8th. BTIG Research increased their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Coya Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Price Performance

COYA opened at $4.55 on Wednesday. The company has a market capitalization of $95.19 million, a price-to-earnings ratio of -4.10 and a beta of 0.25. The business’s 50-day moving average price is $5.58 and its two-hundred day moving average price is $5.96. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $8.29.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. Sell-side analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of COYA. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics during the 3rd quarter worth about $28,000. Lantern Wealth Advisors LLC bought a new position in Coya Therapeutics in the 3rd quarter valued at about $66,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Coya Therapeutics during the second quarter worth approximately $119,000. Prosperity Wealth Management Inc. boosted its holdings in shares of Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after acquiring an additional 3,350 shares during the period. Finally, Jane Street Group LLC grew its position in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.